EUVIMEDEUVIMED entdecken
Fallbericht

Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma

Makiko Urabe, Kenji Ikezawa, Kazuhiro Kozumi, Yugo Kai, Ryoji Takada, Kaori Mukai, Tasuku Nakabori, Hiroyuki Uehara, Hirofumi Akita, Kazuyoshi Ohkawa

Clinical Journal of Gastroenterology · 2024

DOI: 10.1007/s12328-024-01981-4 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Journal of Gastroenterology, 2024. Verfasst von Makiko Urabe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Acinar Cell, Chemoradiotherapy, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic acinar cell carcinoma (PACC) is a rare cancer with no specific treatment. The treatment and chemotherapy for PACC are selected according to pancreatic ductal adenocarcinoma (PDAC). Herein, we describe a recurrent PACC case of an older adult patient. The patient was treated with systemic chemotherapy, chemoradiotherapy, and maintenance therapy based on the pathologic germline BRCA2 variant, resulting in long-term survival. The pathogenic BRCA variant is detected more frequently in patients with PACC than in those with PDAC. The BRCA variant significantly impacts treatment selection and prognosis; therefore, early genomic analysis is recommended when treating PACC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Acinar CellChemoradiotherapyNeoplasm Recurrence, LocalHumansAntineoplastic Combined Chemotherapy ProtocolsAgedMaleMaintenance ChemotherapyBRCA2 ProteinGerm-Line Mutation

Stichwörter der Autor:innen

BRCA variantChemoradiotherapyChemotherapyMaintenance therapyPancreatic cancer

Substanzen

BRCA2 ProteinBRCA2 protein, human

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
  • Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan. ikezawa-ke@oici.jp.
  • Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Zitieren

APA

Urabe, M., Ikezawa, K., Kozumi, K., Kai, Y., Takada, R., Mukai, K., Nakabori, T., Uehara, H., Akita, H., & Ohkawa, K. (2024). Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma. Clinical Journal of Gastroenterology. https://doi.org/10.1007/s12328-024-01981-4

Vancouver

Urabe M, Ikezawa K, Kozumi K, Kai Y, Takada R, Mukai K, et al. Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma. Clinical Journal of Gastroenterology. 2024. doi:10.1007/s12328-024-01981-4

BibTeX
@article{Urabe2024,
  author = {Urabe, Makiko and Ikezawa, Kenji and Kozumi, Kazuhiro and Kai, Yugo and Takada, Ryoji and Mukai, Kaori and Nakabori, Tasuku and Uehara, Hiroyuki and Akita, Hirofumi and Ohkawa, Kazuyoshi},
  title = {Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma},
  journal = {Clinical Journal of Gastroenterology},
  year = {2024},
  doi = {10.1007/s12328-024-01981-4}
}
Kostenlos starten →